Through integrative analyses of human EGFR-mutant lung cancer cell-derived xenografts, PDX models and clinical specimens, we here provide evidence to support a causal link between AST and TKI resistance, reveal the underlying molecular mechanism and offer a potential therapeutic strategy to overcome AST-mediated drug resistance in lung cancer. Here, EGFR is linked to lung carcinoma.